Home > What We Do > Current Clinical Trials

Australian Alzheimer’s Research FOUNDATION is currently seeking participants for the following trials:

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

Study NAME AND WHO IS ELIGIBLE
THE SCHEDULE

COGRX – COG0102 Phase 1

  • Male or female and age is between 50 and 85 years
  • Has an identified, reliable, study partner (e.g. family member)
  • Decline in cognition for > 6 months, consistent with Alzheimer’s disease
  • Must be willing to participate in a lumbar puncture (2 per trial)
  • Weight between 50kgs – 110kgs

  • Weekly visits
  • Daily medication * (tablets)
  • 6 weeks duration

 

Lilly – LLCF/Navigate-AD Phase 2

  • Male or female and age is between 55 and 85 years
  • Has an identified, reliable, study partner (who spends 10+ hours a week with the subject)
  • Diagnosed with mild Alzheimer’s disease
  • Subject must be able to ingest oral medications

  • Monthly visits
  • Daily medication * (tablets)
  • 12 months duration

 

AbbVie – AWARE STUDY Phase 2

  • Male or female and age is between 55 and 85 years
  • Must be diagnosed with mild cognitive impairment or mild Alzheimer’s disease
  • Has an identified, reliable, study partner (e.g. family member)
  • If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 12 weeks prior to randomization

  • Monthly visits for infusions.
  • Monthly medication *
  • 22 months duration
  • Enrolling April 2017

 

Biogen – Engage Phase 3

  • Aged 50 to 85 years old inclusive, at the time of informed consent
  • Has an identified, reliable, study partner (e.g. family member)
  • Must have mild cognitive impairment due to Alzheimer’s disease or diagnosed with Alzheimer’s disease
  • Must have at least 6 years of education or work experience to exclude mental deficits other than mild cognitive impairment or mild Alzheimer’s

  • Monthly visits for infusions.
  • Monthly medication * (dosage dependant on weight)
  • 22 months duration

 

vTv Therapeutics – Steadfast Phase 3

  • Males and females aged 50+ years of age at screening
  • Diagnosis of probable Alzheimer’s disease
  • Must be on a stable dosage of cholinesterase inhibitor / Memantine
  • Subject must be able to ingest oral medications
  • Has an identified, reliable, study partner (who spends 10+ hours a week with the subject)
  • Weight between 45kgs – 110kgs

  • Visits every 3 months
  • Daily medication * (tablets)
  • 21 months duration

 

PAREXEL – Amaranth Phase 2/3

  • Male or female, aged 55 to 85 years inclusive at signing of informed consent form
  • Has an identified, reliable, study partner (e.g., family member)
  • Must have mild cognitive impairment due to Alzheimer’s disease or diagnosed with Alzheimer’s
    disease
  • Must have completed 6 years of formal education and have a history of academic achievement and/or employment sufficient to exclude mental retardation

  • Monthly visits
  • Daily medication * (tablets)
  • 24 months duration

 

* Please note that participants in all studies have a small chance of being placed on a placebo medication